Jacob Beans, NP
Nurse Practitioner · Greenwood Village, CONPI 1457894347
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 220 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 26 manufacturers reported payments, led by AstraZeneca at 25.4% of the total. 2025 is the largest year on record at $1,433, more than ten times the $30 reported in 2021. Among nurse practitioner clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 220 payments — averaging $19.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Sanofi$693
- GSK$589
- Regeneron Healthcare Solutions, Inc.$303
- Harmony Biosciences LLC$210
- Grifols USA, LLC$202
- plus $1K from 20 others
What the payments were for
- Food & beverage$4,186100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 52 | $1,063 |
| Sanofi | 39 | $693 |
| GSK | 47 | $589 |
| Regeneron Healthcare Solutions, Inc. | 16 | $303 |
| Harmony Biosciences LLC | 6 | $210 |
| Grifols USA, LLC | 8 | $202 |
| Philips North America LLC | 7 | $139 |
| Inspire Medical Systems, Inc. | 5 | $123 |
| Insmed, Inc. | 6 | $120 |
| Merck | 4 | $83 |
| Mylan Specialty L.p. | 4 | $83 |
| Actelion Pharmaceuticals US, Inc. | 3 | $74 |
| Boehringer Ingelheim | 3 | $74 |
| Bayer | 3 | $62 |
| Inogen, Inc. | 3 | $61 |
| Avadel CNS Pharmaceuticals, LLC | 2 | $52 |
| Lilly USA, LLC | 2 | $46 |
| Axsome Therapeutics, Inc. | 2 | $30 |
| Gilead | 1 | $26 |
| Jazz Pharmaceuticals Inc. | 1 | $26 |
| 3b Medical, Inc. | 1 | $26 |
| Electromed, Inc. | 1 | $23 |
| Pfizer | 1 | $21 |
| Resmed Corp | 1 | $19 |
| Baxter Healthcare | 1 | $18 |
| Scpharmaceuticals Inc. | 1 | $18 |
How this compares
$4,186 in reported general payments places this provider in the 95th percentile of 1,384 nurse practitioner providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 17 | $235,820 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 159 | $171,032 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 115 | $93,211 |
| Spiriva RespimatTiotropium Bromide | 51 | $42,625 |
| EliquisApixaban | 52 | $40,934 |
| Breo ElliptaFluticasone/Vilanterol | 63 | $40,127 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 58 | $34,616 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 54 | $24,610 |
| SymbicortBudesonide/Formoterol Fumarate | 90 | $23,022 |
| XareltoRivaroxaban | 15 | $14,475 |
| Spiriva HandihalerTiotropium Bromide | 16 | $13,469 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 82 | $12,683 |
| Incruse ElliptaUmeclidinium Bromide | 20 | $11,592 |
| Advair HfaFluticasone Propion/Salmeterol | 28 | $10,937 |
| Arnuity ElliptaFluticasone Furoate | 28 | $10,054 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $74 | $318,481137 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $589 | $257,415324 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Pulmicort Flexhaler | $1,063 | $121,504218 claims |
| PfizerEliquis | $21 | $40,93452 claims |
| MerckDulera | $83 | $5,25511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,384 nurse practitioner providers in Colorado.
Other nurse practitioner in Greenwood Village
- Rianne ClarkGreenwood Village$4K
- Deborah HinnenColorado Springs$388K
- Christina HansonLone Tree$381K
- Kara HartPueblo$142K
- Amy SidorskiAurora$97K
- Lori WenzGrand Junction$54K
- Lisa KeithColorado Springs$52K
- Victoria SegroEnglewood$29K
- Christina ProulxDenver$28K
- Jose Diaz LeoDenver$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.